Blue Horseshoe Stocks: More Options Ideas

BioMarin Pharmaceutical, Inc. BMRN

BioMarin had a really solid performance yesterday after we signaled some contracts in our premarket report, the BMRN 03/16 $80 & 85 Calls. The stock ran from 81.01 to 84.19 facilitating some modest but solid intraday moves in our contracts.

The $80 Calls ran from 4.40-6.00 for a 32% rise, and the $85′s traded from 2.70-3.50, a gain of 26%

With a strong close at 83.28, and a lot of ground to cover to recoup the losses the stock has seen in the month of February, we’ll look for BMRN to establish a more sustained recovery pattern, and we may see some further increases in these contracts, which still have over a month until expiration.

Under Armour, Inc. UAA

We want to formulate an idea for Under Armour on the heels of the company’s earnings report this morning. The stock had already begun to trend off of its bottom a few sessions ago, and despite posting a Q4 loss, sales were better than expected and the stock is gapping up pretty significantly here in the premarket.

We’re going to want to keep tabs on the UAA Weekly $15.50-16.50 Calls, which could bring us sizable gain opportunities in the day or days to come.

Extended Watchlist:

Blue Horseshoe Stocks: MTBC Recap & More

Medical Transcription Billing Corp. MTBC

We caught wind of a potential opportunity in MTBC yesterday morning on a routine scan, and we included it in our extended wathclist for the day. We’re glad that we did, because it turned out to be our top performer for the session!

From a low of 1.43 MTBC shot to a high of 2.87 for an early intraday rip of 101% The stock traded massive volume to the tune of fourteen times the monthly average, while holding the vast majority of its daily gain into the close at 2.40. Based on those factors, we’re very interested to continue tracking MTBC over the course of the next few sessions.

While it does appear overbought at the moment, having been in a bullish pattern for a week now, the stock is currently in blue skies, so there’s no telling where this run might end. One thing’s for sure, when it does begin to pull back off of these impressive new highs, we’ll be waiting in the wings for a subsequent dip-and-rip.

Ocwen Financial Corp. OCN

Yesterday morning we pointed out that OCN was looking massively oversold after falling off a cliff a couple of weeks ago. We also alluded to the fact that it was gapping up significantly in the premarket.

Our vigilance paid off instantly as the stock quickly turned into the bottom bouncer we had it figured for, running 30% intraday from 2.60 to 3.38 on roughly six times the 30-day average. Even if it just returned to its 200DMA, it would spell further gains of 38% so we’ll continue to keep an eye on OCN.


Speaking of bottom-plays, we’re taking notice of NXTD this morning as the stock is gapping up past its current 50DMA of 1.86 in the premarket.

Prior to today it had already begun to bear the look of a stock that was ripening for a rebound, and we’re going to want to pay close attention to its progress in sessions to come looking for the recording of higher highs and higher lows.

Extended Watchlist:

Blue Horseshoe Stocks: BIOC, Options Ideas & More

Biocept, Inc. BIOC
BIOC came off of yesterday morning’s extended watchlist making a big move to start the week. The stock traded up from a low of 1.71 and ran as high as 2.95, registering as an intraday increase of 72%  on heavy volume in the neighborhood of 17X the 30-day running average.

After pulling back slightly into the close at 2.20, BIOC is presently gapping up in the premarket this morning( High of 2.64), so we’re going to keep it on our watchlist for the time being.

The strong session came in conjunction with a positive PR which hit the wires yesterday:

SAN DIEGO, Feb 23, 2015 (GLOBE NEWSWIRE via COMTEX) — Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced that its blood-based diagnostic, OncoCEE-BR(TM), was used to determine hormonal status of metastatic breast cancer patients in a prospective study performed at the Columbia University College of Physicians and Surgeons in New York City. Findings from the Columbia study were recently published in the peer-reviewed journal Clinical and Translational Oncology.>>> FULL PR

Direxion Daily Russia Bear 3X ETF (RUSS)

The idea we brought forth yesterday of monitoring RUSS, which trades inversely with the Russian economy, is probably going to be one that we follow for a longer period of time given the drawn out nature of the events currently playing out in the Ukraine, and how they’re affecting Russia.

That being said, we did see some immediate upward price action as RUSS ran into the close, recording a daily trading range from 12.58 – 13.74, a modest, yet solid 9% appreciation on the day.

Added Note:

We also want to make note of a proposed joint venture in the works between two companies whose stocks we’ve mentioned in the past: First Solar, Inc. FSLR and SunPower Corp. SPWR. Both stocks began to move on word of a possible IPO for a new vehicle to be comprised of existing assets from each party. We’re going to keep them on watch as we await further updates on the situation.

They’re both gapping up further this morning, so we’ll be on the lookout for potential dip-and-rip scenarios caused by profit-taking. In such an event, we’ll be fixating on In-the-money Weekly Calls for options daytrading possibilities.

TEMPE, Ariz. and SAN JOSE, Calif., Feb. 23, 2015 /PRNewswire/ — First Solar, Inc. (FSLR) and SunPower Corp. (SPWR) announced today that they are in advanced negotiations to form a joint YieldCo vehicle (the YieldCo) to which they each expect to contribute a portfolio of selected solar generation assets from their existing portfolio of assets. Upon the execution of a master formation agreement, the parties intend to file a registration statement with the Securities and Exchange Commission (the SEC) for an initial public offering of limited partner interests in the YieldCo (the IPO). >>> FULL PR

Extended Watchlist: